Tag: Biosimilar mAbs

What is the best way to approach biosimilar development?

27th March 2017

Category: Bioanalytical / Biosimilars

Tags: , , ,

By: Dr Terry Gray, Field Marketing Manager,

Part one Monoclonal antibodies have a highly specific targeted action which allows a reduction in side effects compared to small molecule drugs, which has seen them becoming a mainstay of modern medicine. The innate complexity of these molecules allows them to be potent drugs that activate molecular cascades within the immune system. So what does More

Piecing together the biosimilar puzzle: Physicochemical & Functional Analytics

Category: Bioanalytical / Biosimilars

Tags: , , , , , , , ,

By: Dr Terry Gray, Field Marketing Manager,

Part two Read Part One. A fundamental feature of a mAb is its biological structure, as this defines the functional output of the biologic, as illustrated by Figure 2. Figure 2 – The interplay between the structure of a monoclonal antibody, the affinity for interaction and the resulting functional activity. Fundamentally, the sequence of a More

Biosimilars – How similar must they be?

28th April 2011

Category: Biosimilars

Tags: ,

By: Dr Daniel Galbraith, CSO,

The hype over the market for biosimilars remains buoyant; research indicates that the market is likely to be worth almost USD$20 Billion by 2014. This increase is in some part driven by the major Asian players who have well over one third of the market. This push is in many ways due to the strong More

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy